Kamada (KMDA) - Net Assets
Based on the latest financial reports, Kamada (KMDA) has net assets worth ILA265.23 Million ILA (≈ $711.08K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA377.21 Million ≈ $1.01 Million USD) and total liabilities (ILA111.98 Million ≈ $300.21K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check KMDA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA265.23 Million |
| % of Total Assets | 70.31% |
| Annual Growth Rate | 5.95% |
| 5-Year Change | 45.25% |
| 10-Year Change | 257.85% |
| Growth Volatility | 63.12 |
Kamada - Net Assets Trend (2006–2024)
This chart illustrates how Kamada's net assets have evolved over time, based on quarterly financial data. Also explore Kamada asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Kamada (2006–2024)
The table below shows the annual net assets of Kamada from 2006 to 2024. For live valuation and market cap data, see Kamada stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA259.46 Million ≈ $695.61K |
+6.33% |
| 2023-12-31 | ILA244.02 Million ≈ $654.21K |
+38.63% |
| 2022-12-31 | ILA176.02 Million ≈ $471.90K |
-0.45% |
| 2021-12-31 | ILA176.82 Million ≈ $474.06K |
-1.02% |
| 2020-12-31 | ILA178.64 Million ≈ $478.92K |
+32.01% |
| 2019-12-31 | ILA135.32 Million ≈ $362.79K |
+20.42% |
| 2018-12-31 | ILA112.38 Million ≈ $301.28K |
+25.57% |
| 2017-12-31 | ILA89.49 Million ≈ $239.92K |
+34.08% |
| 2016-12-31 | ILA66.74 Million ≈ $178.94K |
-7.95% |
| 2015-12-31 | ILA72.51 Million ≈ $194.39K |
-10.48% |
| 2014-12-31 | ILA80.99 Million ≈ $217.14K |
-9.98% |
| 2013-12-31 | ILA89.97 Million ≈ $241.21K |
+216.87% |
| 2012-12-31 | ILA28.39 Million ≈ $76.12K |
+25.22% |
| 2011-12-31 | ILA22.67 Million ≈ $60.79K |
-14.39% |
| 2010-12-31 | ILA26.49 Million ≈ $71.01K |
-12.15% |
| 2009-12-31 | ILA30.15 Million ≈ $80.83K |
+138.48% |
| 2008-12-31 | ILA12.64 Million ≈ $33.89K |
-81.83% |
| 2007-12-31 | ILA69.57 Million ≈ $186.51K |
-24.07% |
| 2006-12-31 | ILA91.62 Million ≈ $245.63K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Kamada's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2573800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA15.03 Million | 5.79% |
| Other Comprehensive Income | ILA-3.08 Million | -1.19% |
| Other Components | ILA273.25 Million | 105.31% |
| Total Equity | ILA259.46 Million | 100.00% |
Kamada Competitors by Market Cap
The table below lists competitors of Kamada ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Yuxing Film Tech
SHE:300305
|
$371.35 Million |
|
Aarti Drugs Limited
NSE:AARTIDRUGS
|
$371.43 Million |
|
DB Financial Investment Co Ltd
KO:016610
|
$371.48 Million |
|
Bhagiradha Chemicals & Industries Limited
NSE:BHAGCHEM
|
$371.49 Million |
|
Chongqing Sifang New Material Co. Ltd.
SHG:605122
|
$371.25 Million |
|
Shivalik Bimetal Controls Limited
NSE:SBCL
|
$370.98 Million |
|
Thessaloniki Port Authority SA
AT:OLTH
|
$370.94 Million |
|
Sinomach General Machinery Science Technology Co Ltd
SHG:600444
|
$370.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kamada's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 244,021,000 to 259,464,000, a change of 15,443,000 (6.3%).
- Net income of 14,462,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 6,427,000.
- Other factors increased equity by 7,408,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA14.46 Million | +5.57% |
| Other Comprehensive Income | ILA-6.43 Million | -2.48% |
| Other Changes | ILA7.41 Million | +2.86% |
| Total Change | ILA- | 6.33% |
Book Value vs Market Value Analysis
This analysis compares Kamada's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 507.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 366.21x to 507.68x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | ILA6.56 | ILA2401.00 | x |
| 2008-12-31 | ILA0.96 | ILA2401.00 | x |
| 2009-12-31 | ILA1.20 | ILA2401.00 | x |
| 2010-12-31 | ILA1.06 | ILA2401.00 | x |
| 2011-12-31 | ILA0.82 | ILA2401.00 | x |
| 2012-12-31 | ILA0.99 | ILA2401.00 | x |
| 2013-12-31 | ILA2.69 | ILA2401.00 | x |
| 2014-12-31 | ILA2.25 | ILA2401.00 | x |
| 2015-12-31 | ILA2.00 | ILA2401.00 | x |
| 2016-12-31 | ILA1.83 | ILA2401.00 | x |
| 2017-12-31 | ILA2.35 | ILA2401.00 | x |
| 2018-12-31 | ILA2.77 | ILA2401.00 | x |
| 2019-12-31 | ILA3.33 | ILA2401.00 | x |
| 2020-12-31 | ILA3.96 | ILA2401.00 | x |
| 2021-12-31 | ILA3.94 | ILA2401.00 | x |
| 2022-12-31 | ILA3.79 | ILA2401.00 | x |
| 2023-12-31 | ILA4.55 | ILA2401.00 | x |
| 2024-12-31 | ILA4.73 | ILA2401.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kamada utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.57%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.99%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.43x
- Recent ROE (5.57%) is above the historical average (-14.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -32.91% | -170.39% | 0.11x | 1.82x | ILA-29.85 Million |
| 2008 | -98.45% | -81.81% | 0.36x | 3.33x | ILA-13.71 Million |
| 2009 | -73.08% | -147.09% | 0.24x | 2.09x | ILA-25.05 Million |
| 2010 | -57.29% | -41.83% | 0.40x | 3.46x | ILA-17.82 Million |
| 2011 | -15.40% | -6.25% | 0.65x | 3.77x | ILA-5.76 Million |
| 2012 | 0.92% | 0.36% | 0.82x | 3.14x | ILA-2.58 Million |
| 2013 | 0.49% | 0.63% | 0.51x | 1.55x | ILA-8.55 Million |
| 2014 | -15.60% | -17.57% | 0.60x | 1.48x | ILA-20.74 Million |
| 2015 | -15.54% | -16.07% | 0.69x | 1.41x | ILA-18.52 Million |
| 2016 | -10.09% | -8.69% | 0.78x | 1.49x | ILA-13.41 Million |
| 2017 | 7.71% | 6.71% | 0.84x | 1.36x | ILA-2.05 Million |
| 2018 | 19.84% | 19.48% | 0.83x | 1.23x | ILA11.06 Million |
| 2019 | 16.44% | 17.49% | 0.73x | 1.28x | ILA8.72 Million |
| 2020 | 9.59% | 12.86% | 0.63x | 1.18x | ILA-723.80K |
| 2021 | -1.26% | -2.15% | 0.33x | 1.80x | ILA-19.91 Million |
| 2022 | -1.32% | -1.79% | 0.40x | 1.83x | ILA-19.92 Million |
| 2023 | 3.39% | 5.81% | 0.40x | 1.45x | ILA-16.12 Million |
| 2024 | 5.57% | 8.99% | 0.43x | 1.43x | ILA-11.48 Million |
Industry Comparison
This section compares Kamada's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $576,709,811
- Average return on equity (ROE) among peers: 22.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kamada (KMDA) | ILA265.23 Million | -32.91% | 0.42x | $371.30 Million |
| Canzon Israel Ltd (CNZN) | $4.23 Million | -112.18% | 0.24x | $1.81 Million |
| Intercure (INCR) | $397.67 Million | -17.05% | 0.92x | $36.39 Million |
| Intelicanna Ltd (INTL) | $4.41 Billion | 12.46% | 8.24x | $10.11 Million |
| Nextage Therapeutics Ltd (NXTG) | $3.66 Million | -57.11% | 0.64x | $5.79 Million |
| Rekah Pharmaceutical Industry Ltd (REKA) | $144.62 Million | -15.54% | 1.04x | $35.99 Million |
| Seach Medical Group Ltd (SEMG) | $31.38 Million | 9.42% | 0.14x | $22.18 Million |
| Teva Pharmaceutical Industries Ltd (TEVA) | $49.90 Million | 15.23% | 1.79x | $1.09 Billion |
| Together Startup Network Ltd (TGTR) | $549.00K | 387.98% | 0.54x | $9.92 Million |
| Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) | $143.82 Million | -22.70% | 0.32x | $28.21 Million |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more